

PHARMACY PRE-AUTHORIZATION CRITERIA



DRUG (S)	Duzallo (lesinurad/allopurinol) Zurampic (lesinurad)
POLICY #	14101
INDICATIONS	<p>Zurampic is indicated for the adjunct treatment of hyperuricemia associated with gout (in combination with a xanthine oxidase inhibitor, ie, Allopurinol or Uloric) in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.</p> <p>Duzallo is indicated for the treatment of hyperuricemia associated with gout in patients not achieving target serum uric acid levels with allopurinol alone.</p>
CRITERIA	<p>ConnectiCare considers Zurampic and Duzallo to be medically necessary in adults who meet all of the following criteria:</p> <ul style="list-style-type: none"> • Patient has clinically diagnosed hyperuricemia associated with gout • Patient has not achieved a target serum uric acid level using allopurinol (Zyloprim) in a dose of at least 300mg daily (200mg in renal impairment) <p>AND</p> <ul style="list-style-type: none"> • Patient has not achieved a target serum uric acid level using febuxostat (Uloric) 80mg daily • Patient has a serum uric acid level above 6mg/dl despite use of Uloric • Patient is not using Zurampic as monotherapy
LIMITATIONS	Zurampic is not recommended for the treatment of asymptomatic hyperuricemia
REFERENCES	<ol style="list-style-type: none"> 1. Duzallo full prescribing information. Ironwood Pharmaceuticals, Inc., Cambridge, MA 2. Zurampic full prescribing information. Ironwood Pharmaceuticals, Inc., Cambridge, MA
P&T REVIEW HISTORY	11/16, 11/17, 1/18, 11/18
REVISION RECORD	11/17, 1/18